#### Certificate of Electronic Transmission Under 37 C.F.R. 1.8

I hereby certify that this correspondence is being electronically transmitted to the United States Patent and Trademark Office, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on January 31, 2011.

> /Jane R. Leonard/ Jane R. Leonard

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jeremy Clark Examiner:

McIntosh III

Patent No.:

7,429,572

Group Art Unit:

1623 Confirmation Number: 5481

Serial No.: Filed:

10/828,753 April 21, 2004

Docket No.:

E7524-00042

Issue Date: Title:

September 30, 2008

Modified Fluorinated Nucleoside Analogues

### REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.323

Certificate of Correction Branch Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### Dear Sir:

The patentee of the above-referenced patent, through its attorney, hereby request issuance of a Certificate of Correction. A certificate is required to correct errors made without deceptive intent.

- Column 4. In. 23, "Ribivarin" should read "Ribavirin"; 1)
- 2) Column 5, ln. 54, "world population" should read "world's population";
- Column 6, In. 2, "hepatitis C flavivirus" should read "hepatitis C virus"; 3)
- 4) Column 8, ln. 49, "piperidenes" should read "piperidines";

- 5) Column 11, ln. 64, "R2 and R" should read "R2 and R2";
- 6) Column 12, ln. 22, "R is an" should read "R6 is an";
- Column 14, In. 2, "fluroination" should read "fluorination";
- 8) Column 15, In. 44, "therapeuric" should read "therapeutic";
- Column 15, ln. 53, "Intraperitneal" should read "Intraperitoneal";
- 10) Column 18, Il. 23 24, "N<sup>6</sup>-allcylaminopurine, N<sup>6</sup>-thioallcyl purine" should read "N<sup>6</sup>-allylaminopurine, N<sup>6</sup>-thioallyl purine";
- 11) Column 18, In. 27, "4-mercaptopyrmidine" should read "4-mercaptopyrimidine";
- 12) Column 18, ln. 33, "C6-Br-vinyl pyriniidine" should read "C6-Br-vinyl pyrimidine";
- 13) Column 18, In. 49, "ailcaryl" should read "alkaryl";
- Column 18, In. 51, "ailcyl" should read "alkyl";
- 15) Column 18, In. 52, "chioro" should read "chloro";
- 16) Column 18, In. 56, "alkoxyalicyl" should read "alkoxyalkyl";
- 17) Column 19, ln. 13, "O-acetyimandelyl" should read "O-acetylmandelyl";
- 18) Column 19, Il. 23 24, "ct-trifluoromethyl-phenylacetyl" should read "trifluoromethyl-phenylacetyl";
- 19) Column 20, ln. 60, "R2 and R" should read "R2 and R2";
- 20) Column 21, ln. 16, "R can be linked" should read "R2" can be linked";
- 21) Column 23, ln. 1, "R3" should read "R3";
- 22) Column 25, ll. 33 34, "R<sup>2</sup>, is H" should read "R<sup>2</sup>', is H";

Patent No. 7,429,572 Request for Certificate of Correction

Column 25, ln. 63, "R2 is H" should read "R2' is H": 23)

- Column 36, In. 11, "raceniate" should read "racemate": 24)
- Column 39, Il. 3 5, "tartarate, ascorate, a-glycerophosphate" should read "tartrate, 25) ascorbate, a-glycerophosphate";
- Column 47, ln. 61, "declosed in" should read "disclosed in"; 26)
- Column 48, ln. 12, "ribavirn" should read "ribavirin"; 27)
- Column 61, In. 29, "potentcy" should read "potency"; and 28)
- Claim 5, Column 65, ln. 1, "(2')-2'-deoxy-2'-fluoro-2'-C-methyl nucleoside" should read 29) "A (2'R)-2'-deoxy-2'-fluoro-2'-C-methyl nucleoside".

The Corrections made herein are believed to be only typographical in nature and not believed to involve such changes that would constitute new matter or require examination.

It is respectfully requested that a Certificate of Correction be issued pursuant 35 U.S.C. § 255 to correct the typographical errors. Enclosed herewith is a copy of a proposed Certificate of Correction indicating the errors and corrections.

Pursuant to 37 C.F.R. § 1.20(a), the Commissioner is hereby authorized to charge the requisite fee of \$100.00 or credit any overpayment to Duane Morris LLP Deposit Account No. 04-1679

Respectfully submitted,

Duane Morris LLP 1180 West Peachtree St., Suite 700 Atlanta, GA 30309-3448 (404) 253-6900

/Joseph M. Bennett-Paris/ Date: January 31, 2011

Joseph M. Bennett-Paris, Ph.D.

Reg. No. 47,226

75715

DM2\2644854.1

U.S. Patent and Trademark Office; U.S. DEPART MENT OF COMMERCE.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTO-1050)

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

		Page	1	_of_	4
PATENT NO.	: 7.429.572				

APPLICATION NO.: 10/828.753

ISSUE DATE : September 30, 2008

INVENTOR(S) : Jeremy Clark

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- 1) Column 4, ln. 23, "Ribivarin" should read "Ribavirin";
- 2) Column 5, ln. 54, "world population" should read "world's population";
- 3) Column 6, ln. 2, "hepatitis C flavivirus" should read "hepatitis C virus";
- 4) Column 8, ln. 49, "piperidenes" should read "piperidines";
- 5) Column 11, ln. 64, "R2 and R" should read "R2 and R2";
- Column 12, ln. 22, "R is an" should read "R<sup>6</sup> is an";
- Column 14, In. 2, "fluroination" should read "fluorination";
- Column 15, In. 44, "therapeuric" should read "therapeutic";
- 9) Column 15, ln. 53, "Intraperitneal" should read "Intraperitoneal";

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Joseph M. Bennett-Paris, Ph.D.

Duane Morris LLP

Duane Mons LLP

1180 W. Peachtree Street, NW, Suite 700

This collection of information is required by 37 CFR, 1322, 1323, and 1324. The information is required to obtain or retain a benefit by the public which is to the rad by the USFFO to proceed an application. Conditionality is governed by \$0.150. CE2 and \$7 CFR. 114. This Collection is estimated to 1 hour to complete, including gathering, preparing, and submitting the completed application form to the USFFO. Time will very depending upon the individual case. Any comments on the animumal of time your require to complete the form and/or suggestion for reducing the bodient, section upon the individual case. Any comments on the animumal office your require to complete the form and/or suggestion for reducing the bodien, section to the Conference of the Conference

U.S. Patent and Trademark Office; U.S. DEPART MENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

[Also Form PTO-1050]

# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 2 of 4

PATENT NO. : 7,429,572

APPLICATION NO.: 10/828.753

ISSUE DATE : September 30, 2008

INVENTOR(S) : Jeremy Clark

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- Column 18, Il. 23 24, "N<sup>6</sup>-allcylaminopurine, N<sup>6</sup>-thioallcyl purine" should read "N<sup>6</sup>-allylaminopurine, N<sup>6</sup>-thioallyl purine";
- 11) Column 18, ln. 27, "4-mercaptopyrmidine" should read "4-mercaptopyrimidine";
- 12) Column 18, ln. 33, "C6-Br-vinyl pyriniidine" should read "C6-Br-vinyl pyrimidine";
- 13) Column 18, ln. 49, "ailcaryl" should read "alkaryl";
- 14) Column 18, ln. 51, "ailcyl" should read "alkyl";
- Column 18, ln. 52, "chioro" should read "chloro";
- Column 18, ln. 56, "alkoxyalicyl" should read "alkoxyalkyl";
- 17) Column 19, ln. 13, "O-acetyimandelyl" should read "O-acetylmandelyl";

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Joseph M. Bennett-Paris, Ph.D.

Duane Morris LLP

1180 W. Peachtree Street, NW, Suite 700

This obligation of incometion is required by 2 CEPR -1322\_132\_2 and 1323\_The information is required to obtain or mich a beautify by the complete of the property of the complete of the compl

Approved for use through 08/31/2013, OMB 0651-0033
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## (Also Form PTO-1050)

#### UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 3 of 4

: 7.429.572 PATENT NO. APPLICATION NO.: 10/828,753

ISSUE DATE : September 30, 2008

INVENTOR(S) : Jeremy Clark

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- Column 19, Il. 23 24, "ct-trifluoromethyl-phenylacetyl" should read "trifluoromethyl-18) phenylacetyl";
- Column 20, ln. 60, "R2 and R" should read "R2 and R2"; 19)
- Column 21, ln. 16, "R can be linked" should read "R2" can be linked"; 20)
- Column 23, ln. 1, "R3" should read "R3": 21)
- Column 25, 1l. 33 34, "R2, is H" should read "R2'. is H": 22)

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Joseph M. Bennett-Paris, Ph.D.

Duane Morris LLP

1180 W. Peachtree Street, NW, Suite 700

This collection of Information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.4. This collection is estimated to late 1.01 bout to complete, including agriculture of the complete displacation from the IMPTO. These wite ory depending upon the "succession" and standarding the completed application from the IMPTO. These wite ory depending upon the "succession" and standarding the completed application of the IMPTO. These wite ory depending upon the "succession" and the IMPTO. comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

### U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 4 of 4

PATENT NO. : 7,429,572

APPLICATION NO.: 10/828,753

ISSUE DATE : September 30, 2008

INVENTOR(S) : Jeremy Clark

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- 23) Column 25, ln. 63, "R2 is H" should read "R2' is H";
- 24) Column 36, ln. 11, "raceniate" should read "racemate";
- 25) Column 39, Il. 3 5, "tartarate, ascorate, a-glycerophosphate" should read "tartrate, ascorbate, α-glycerophosphate";
- 26) Column 47, ln. 61, "declosed in" should read "disclosed in";
- Column 48, ln. 12, "ribavirn" should read "ribavirin";
- 28) Column 61, ln. 29, "potentcy" should read "potency"; and
- 29) Claim 5, Column 65, ln. 1, "(2')-2'-deoxy-2'-fluoro-2'-C-methyl nucleoside"  $\frac{1}{2}$  should read "A (2'R)-2'-deoxy-2'-fluoro-2'-C-methyl nucleoside".

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Joseph M. Bennett-Paris, Ph.D.

Duane Morris LLP

1180 W. Peachtree Street, NW. Suite 700

This collection of information is required by 37 CPR 1,322, 1,323, and 1,324. The information is required to obtain or retain a benefit by the public which is to fill one by the USPTO is process) and application. Confidentiality is growned by 35 USs. 4,122 and 37 CPR 1,41. This locition is estimated to take 10 hour to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time when you depending upon the individual case. Any commence on the amount of time you require to complete the form and/or supported for individual case. Any commence on the amount of time you require to complete the form and/or supported for individual case. Any commence on the amount of time you require to complete the form and/or supported for reducing the Society and the Complete Co